Steward Health Care System

Return to Results

Extension to CFTY720D2309 (24-month Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg and 1.25 mg Fingolimod [FTY720] Administ

new search

Trial Conditions
  • Multiple Sclerosis
What is the purpose of this trial?

This extension study is designed to evaluate the long-term safety, tolerability and efficacy of FTY720 in patients with multiple sclerosis.

Date & Status

Completed

Who can Participate?

Eligibility

Ages:
20  - 57 

Gender:
Both

Eligibility

Inclusion Criteria:

- Patients with relapsing-remitting disease who completed the 24 month core study with
or without 24 months on study drug.

Exclusion Criteria:

- Other chronic diseases and conditions: of the immune system, malignancies, macular
edema, diabetes, respiratory, cardiovascular.

- Active systemic bacterial, viral or fungal infections.

- Nursing and pregnant women.

Other protocol-defined inclusion/exclusion criteria may apply.

Gender: Both
Steward Physician(s)
  • Novartis Pharmaceuticals
Facilities
  • St. Elizabeth's Medical Center - Completed
Trial Interventions
Drug
  • FTY720
Physician Researcher

Investigator Name:

  • Novartis Pharmaceuticals

Other Information

Sponsor: Novartis Pharmaceuticals
Phase: Phase 3
Trial ID: NCT00774670
Volunteers:  Not Accepting Healthy Volunteers

new search

Connect with Steward

Visit Our Twitter Feed Visit Our Facebook Page Email This Page Print This Page

Subscribe to our patient e-newsletter

Copyright © 2014 Steward Health Care
Connect Healthcare Panacea CMS Solutions